Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial).

"CONFLICT OF INTEREST Christian Marth reports consulting fees from Roche, Novartis, Amgen, MSD, AstraZeneca, Pfizer, PharmaMar, Cerulean, Vertex, Tesaro, GSK, and Seagen; honoraria from Roche, Novartis, Amgen, MSD, AstraZeneca, PharmaMar, Tesaro, GSK, and Seagen; support for attending meetings from Roche and AstraZeneca; and participation on data safety monitoring or advisory boards for Roche, Novartis, Amgen, MSD, AstraZeneca, Pfizer, PharmaMar, Cerulean, Vertex, Tesaro, GSK, and Seagen. Klaus Kaae Andersen is an employee of and holds stock in AstraZeneca. Karoliina M. Aro reports payments or honoraria from Gedeon Richter. Maria de Lurdes Batarda reports support for attending meetings and/or travel from AstraZeneca. Anne Weng Ekmann‐Gade has received honoraria for consultation from AstraZeneca (this study). Ulla‐Maija Haltia has received honoraria for consultation from AstraZeneca (this study). Christian Marth has received honoraria for consultation from AstraZeneca (this study). Maria de Lurdes Batarda has received honoraria for consultation from AstraZeneca (this study). Jesper Hansen is an employee of AstraZeneca. Heini Lassus has received honoraria for consultation or lectures from AstraZeneca (this study), GSK, Eisai, and Roche. Kristina Lindemann reports consulting fees from AstraZeneca (paid to her institution); participation on boards for GSK, MSD, and Eisai; and leadership or fiduciary roles with the Nordic Society of Gynaecological Oncology and the Cancer Registry of Norway. Stephan Polterauer reports honoraria for consultation from AstraZeneca, Celgene, GSK, Eisai, MSD, PharmaMar, Roche, Roche Diagnostics, Meda Pharma, Tesaro, and Vifor Pharma; honoraria for lectures from AstraZeneca, Eisai, MSD, GSK, Tesaro, MedAhead, and KLI; and participation on advisory boards for AstraZeneca, Eisai, MSD, GSK, Tesaro, and PharmaMar. The other authors made no disclosures."

"FUNDING INFORMATION This study was funded by AstraZeneca and is part of an alliance between AstraZeneca and Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc (Kenilworth, New Jersey)."